ImmunoGenesis

ImmunoGenesis is a biotech company in Houston, United States, founded in 2019. It has raised $15.3M across 2 rounds, most recently a $10.8M Grant in December 2025.

We're breaking down walls around cancer

Headquarters
Houston, Texas
Employees
11–50
Founded
2019
Total Funding
$15.3M
Last Round
$10.8M GrantDec 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.

About

ImmunoGenesis is a clinical-stage immuno-oncology company developing therapies for immune-excluded tumors. Its drug-development strategy targets mechanisms that keep activated T cells outside the tumor bed and limit responses to existing checkpoint inhibitors. The company's lead approach includes IMGS-001, a cytotoxic immune-checkpoint inhibitor designed to break down barriers blocking T cells, provide PD-1 blockade, and activate those cells when they reach the tumor.

Summary

It lists 11–50 employees. It has raised $15.3M in total across 2 rounds, most recently a $10.8M Grant round in Dec 2025. Investors include Cancer Focus Fund.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
GrantDec 2025
$10.8M

Sign up to see all 2 events

Funding: Corporate Round through Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ImmunoGenesis on Indexed.vc
<a href="https://indexed.vc/companies/immunogenesis"><img src="https://indexed.vc/api/badge/company/immunogenesis" alt="ImmunoGenesis on Indexed.vc" width="260" height="76" /></a>